On January 13, 2021, BJAJ Medical Technology Group, China's leading manufacturer of biomimetic mineralized collagen artificial bone repair materials, successfully listed on the Shanghai Stock Exchange.
In recent years, with the acceleration of China’s population aging process and the continuous improvement of the people’s requirements for the quality of medical services, the number of orthopedic, neurosurgery, and dental surgeries that demand bone grafts has continued to increase, and the bone repair material market has followed From the perspective of the capital market, BJAJ, a leader in artificial bone repair materials in China, has also entered the fast lane of development.
BJAJ is a national high-tech enterprise focusing on the research and development, production and sales of high-end biomedical materials and related medical device products. The main products are mineralized collagen artificial bone repair products used in orthopedics, oral or plastic surgery, and neurosurgery.
For this listing, BJAJ plans to issue no more than 33.33 million A shares, accounting for no less than 25.00% of the total share capital after the issuance. BJAJ plans to raise approximately 789 million yuan after deducting issuance expenses, of which 558.6696 million yuan will be used. In the Aojing Health Science and Technology Industrial Park construction project, RMB 45.85 million was used for the research and development project of mineralized collagen/polyester artificial bone and collagen sponge, RMB 84,303,500 was used for the construction of marketing network, and RMB 100 million was used to supplement working capital.
Leading company in artificial bone repair materials
In the field of orthopedics, bone defects due to trauma, bone tumors, degenerative diseases and other reasons are very common. When bone defect repair or bone graft fusion is required, the most ideal way is to achieve self-repair and fusion of bone through the function of tissue regeneration. However, in many cases, human bones cannot repair themselves well, such as large-scale bone defects, nonunion, delayed bone healing, and inter-articular fusion. At this time, bone implant materials are needed.
Since its establishment, BJAJ has mainly conducted research and development in the field of mineralized collagen artificial bone repair materials. Starting from the urgent clinical needs of bone defect repair and bone graft fusion, it has an in-depth understanding of the specific requirements for bone implant materials in different departments and procedures. The hierarchical structure and formation process of natural bones have carried out in-depth and detailed scientific exploration. After years of bone repair material research and product design and development, a set of bone material bionic design principles and preparations that simulate the composition, structure and formation process of natural bone have been developed Technology, and developed a mineralized collagen artificial bone repair material that can meet the needs of clinical bone defect repair, and established an in vitro bionic mineralization technology platform with complete intellectual property rights.
Relying on the above-mentioned technology platform, BJAJ has carried out product research and development in response to the clinical needs of different departments, and has successively launched a series of mineralized collagen artificial bone repair products. Up to now, BJAJ's products have obtained the China Class III medical device product registration certificate, which are used for bone defect repair in orthopedics, oral or plastic surgery, and neurosurgery. They have been used in Peking Union Medical College Hospital, Shanghai Sixth People's Hospital, More than 400 hospitals, including Wuhan Tongji Hospital and other domestic well-known tertiary hospitals, have used more than one million clinical cases. At the same time, four products have obtained the US FDA 510(k) market access permit for orthopedic bone defect repair, becoming China’s first and currently the only domestic artificial bone that has obtained the US FDA 510(k) market access permit Repair the product.
It is worth mentioning that in December 2018, the Ministry of Science and Technology announced that among the 87 innovative medical device products selected in the "Innovative Medical Device Product Catalog (2018)", BJAJ's artificial bone repair materials were listed as an "International Original" project.
BJAJ is increasing research and development around artificial bone repair materials and its adjacent fields to continue to enrich its product line. According to data, BJAJ plans to start clinical trials of mineralized collagen/polyester composite artificial bone repair materials and collagen sponges in 2021, and carry out collagen dressings, oral guided tissue regeneration membranes, and skull repair from 2021 to 2025. Customized body, neural tube sheath, artificial dura (spine) membrane, clinical trials of artificial skin, and development of spine mineralized collagen artificial bone repair materials for the US market. US FDA 510(k) application work.